title: Biochemical effects of Navelbine on tubulin and associated proteins.
abstract: Navelbine (NVB) or 5' nor-anhydro-vinblastine was shown to present a broader antitumor activity and to induce fewer side effects than vinblastine (VBL) or vincristine (VCR). The possible mechanisms of these differences were analyzed with in vitro methods. At substoichiometric concentrations, the three drugs inhibit microtubule assembly. NVB, in comparison with VCR and VBL, is shown to have a lower inhibitory effect. At stoichiometric concentrations, the three drugs are able to induce tubulin aggregation into spirals and paracrystals. This process involves a microtubule-associated protein (MAPs) family referred to as Tau and is inhibited by another MAPs family referred to as MAP2. However, dramatic quantitative and qualitative differences are observed between NVB and VLB or VCR in TAU-induced aggregation of tubulin. The rate and extent of NVB-induced tubulin aggregation is much lower. With NVB, only certain TAU isoforms are able to induce paracrystals, while all TAU isoforms may contribute to VCR-induced or VBL-induced paracrystals. The TAU isoforms that are not able to induce crystallization with NVB, at least in a certain range of concentrations, are probably involved in mitotic microtubules--the hypothetical antitumoral target of vinca alkaloids (VAS). The present work shows for the first time that an anticancer drug is able to discriminate between the various types of microtubules. A next step will be to investigate whether this property is limited to a modulating effect of the various TAU isoforms on the affinity of VAS for tubulin. These biochemical investigations will be extended to tubulins extracted from tumor cell lines in order to further discriminate NVB from the other VAS.
authors.affiliation: Inserum U96, Hôpital de Kremlin-Bicêtre, Bicetre, France.
authors.forename: A
authors.initials: A
authors.lastname: Fellous
authors.forename: R
authors.initials: R
authors.lastname: Ohayon
authors.forename: T
authors.initials: T
authors.lastname: Vacassin
authors.forename: S
authors.initials: S
authors.lastname: Binet
authors.forename: H
authors.initials: H
authors.lastname: Lataste
authors.forename: A
authors.initials: A
authors.lastname: Krikorian
authors.forename: J P
authors.initials: JP
authors.lastname: Couzinier
authors.forename: V
authors.initials: V
authors.lastname: Meininger
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents; D003460:Crystallization; D004586:Electrophoresis; D007536:Isomerism; D008869:Microtubule-Associated Proteins / Q000145:classification / Q000378:metabolism / Q000502:physiology*; D008870:Microtubules / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D051381:Rats; D014404:Tubulin / Q000378:metabolism*; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014750:Vincristine / Q000494:pharmacology; D000077235:Vinorelbine; D016875:tau Proteins
chemical_list: D000970:Antineoplastic Agents; D008869:Microtubule-Associated Proteins; D014404:Tubulin; D016875:tau Proteins; D014750:Vincristine; D014747:Vinblastine; D000077235:Vinorelbine